IP Library Granted Patent US 10,293,081
Granted Patent B2
US 10,293,081 · App. 15/531,442 · Granted May 21, 2019

High-strength crystallized glass ceramic comprising wollastonite, hydroxyapatite and akermanite

Inventors: Mi Young Ryu (Gyeonggi-do, KR); Sung Nam Park (Gyeonggi-do, KR); Jun Hyuk Seo (Gyeonggi-do, KR); Hyun Seung Ryu (Gyeonggi-do, KR)
Assignee: BIOALPHA CORPORATION
A61L27/10A61L27/12C03C4/0007C03C10/00C03C10/0009A61L2430/38C03C2204/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,293,081
App. No.
15/531,442
Granted
May 21, 2019
Kind
B2
Abstract

The present invention relates to a crystallized glass ceramic comprising 30 wt % to 40 wt % of each of CaSiO 3 , Ca 10 (PO 4 ) 6 (OH) 2 , and Ca 2 Mg(Si 2 O 7 ); a crystallized glass ceramic composition comprising CaSiO 3 , Ca 10 (PO 4 ) 6 (OH) 2 , and Ca 2 Mg(Si 2 O 7 ) in a predetermined weight ratio; a bone graft material comprising the glass ceramic; and an intervertebral spacer or medical device for replacement of bone tissue, which is manufactured using the bone graft material.

Claims (10)

1. A crystallized glass ceramic comprising CaSiO 3 , Ca 10 (PO 4 ) 6 (OH) 2 , and Ca 2 Mg(Si 2 O 7 ) at a weight ratio of 30 to 40:30 to 40:30 to 40.

2. The crystallized glass ceramic of claim 1 , wherein CaSiO3 comprises a wollastonite, Ca 10 (PO 4 ) 6 (OH) 2 comprises a hydroxyapatite (HA), and Ca 2 Mg(Si 2 O 7 ) comprises an akermanite.

3. The crystallized glass ceramic of claim 1 , wherein the crystallized glass ceramic has increased compressive strength or flexural strength compared to glass ceramics comprising CaSiO 3 and Ca 10 (PO 4 ) 6 (OH) 2 due to Ca 2 Mg(Si 2 O 7 ).

4. The crystallized glass ceramic of claim 1 , wherein the crystallized glass ceramic is formed by sintering at a temperature of about 850° C. to about 1,100° C.

5. The crystallized glass ceramic of claim 1 , which is manufactured by sintering a glass ceramic composition, wherein the glass ceramic composition is manufactured by a process comprising boiling a raw composition comprising SiO 2 , hydroxyapatite, Ca(OH) 2 , MgO, CaF 2 , and B 2 O 3 ,

wherein the raw composition comprises SiO 2 hydroxyapatite, Ca(OH) 2 , MgO, CaF 2 at a weight ratio of 25 to 35:25 to 35:18 to 22:4 to 6:4 to 5.

6. A bone graft material comprising the glass ceramic according to claim 1 .

7. An intervertebral spacer or medical device for replacement of bone tissue: manufactured using the bone graft material of claim 6 ; or, comprising the bone graft material of claim 6 .

8. The intervertebral spacer or medical device of claim 7 , wherein the intervertebral spacer or medical device has compressive strength in a range of about 3,000 N to about 35,000 N or the torsional strength in a range of about 0.6 Nm to about 1.5 Nm.

9. The intervertebral spacer or medical device of claim 7 , wherein the intervertebral spacer or medical device is manufactured using a bone graft material, wherein the bone graft material comprises a dense molded product having a value of relative density corresponding to about 95% or higher relative to that of theoretical density.

Assignments (1)
MERGER Recorded Sep 2, 2021
From: BIOALPHA CORPORATION
To: CG BIO CO., LTD.
Reel/Frame 057364/0551 →
Priority Claims (2)
KR 10-2014-0169052 · Nov 28, 2014 · national
KR 10-2015-0069925 · May 19, 2015 · national
Continuity (1)
Related Publication 20180028716A1 · Feb 1, 2018